Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 734 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Diseases Clear all

Conditions: Primary Biliary Cholangitis
Interventions: Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Biliary Cancer
Interventions: Gemcitabine, docetaxel, and capecitabine; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Cholestasis
Interventions: Omegaven; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 2 Weeks to 18 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Biliary Cirrhosis
Interventions: LUM001; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 10 more

Conditions: Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
Interventions: INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody; Drug · Biological
Lead sponsor: Intensity Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more

Conditions: Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions: Vancomycin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions: capecitabine, gemcitabine hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cholestasis
Interventions: tauroursodeoxycholic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 20 Days
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Jackson, Mississippi • Cincinnati, Ohio

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions: Gemcitabine, Cisplatin, Sorafenib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Biliary Cirrhosis
Interventions: ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more

Conditions: Cancer
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2015
U.S. locations: 1
States / cities: Duarte, California

Conditions: Liver Disease
Interventions: Intravenous Lipid Emulsion Comprised of Fish Oil; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 14 Days to 24 Months
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gallbladder Diseases
Interventions: Not listed
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
Interventions: Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment; Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Nashville, Tennessee

Conditions: Cholestasis
Interventions: Intralipid 20% I.V. Fat Emulsion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 1 Year
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more

Conditions: Cholecystitis, Acute, Cholelithiasis, Nausea, Postoperative, Vomiting, Postoperative, Pain, Postoperative
Interventions: Acupuncture; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cholecystitis, Acute, Cholecystitis, Chronic
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 90 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions: Seribantumab; Drug
Lead sponsor: Elevation Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more

Conditions: Cholestasis
Interventions: sincalide; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 30 Days
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 6
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Rochester, New York + 3 more

Conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Bladder Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Transitional Cell Carcinoma of the Bladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis, pharmacological study, cisplatin; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 3
States / cities: Boston, Massachusetts • Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Biliary Cancer, Cholangiocarcinoma
Interventions: Gemcitabine, Irinotecan, Panitumumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Oncologic Surgery, Cancer, Cancer Surgery, Hepatic Cancer, Gastric (Cardia, Body) Cancer, Biliary Tract Cancer, Pancreatic Cancer Resectable, Gynecologic Cancers, Gastrointestinal Cancers, Colorectal Cancer, Minimally Invasive Surgical Procedures
Interventions: Local Anesthesia, Laparoscopic Transversus Abdominis Plane block; Procedure
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Neoplasms, Bile Duct Neoplasms
Interventions: Oxaliplatin, Capecitabine, Sorafenib; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

GTX Regimen for Biliary Cancers

A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder

Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants

Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury

Comparing the Outcomes of Laparoscopic Cholecystectomy vs. Robotic Cholecystectomy

Programs To Support You During Chemotherapy

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Acupuncture for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

Study of Pain Perception Between Males and Females Following Laparoscopic Cholecystectomy

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma